Digital illustration of a healthy blood vessel

Hydroxychloroquine and AAV: Unveiling the Potential for Infection Prevention

Theo Raines monogram
Theo Raines in Health & Wellness October 2026 • 4 min read.

"Exploring the Role of Hydroxychloroquine in Protecting Patients with Antineutrophil Cytoplasm Antibody-Associated Vasculitis"


Antineutrophil cytoplasm antibody-associated vasculitis (AAV) is a group of autoimmune diseases causing inflammation of small blood vessels. While treatments like rituximab have revolutionized AAV management, they also increase the risk of infections. This is where hydroxychloroquine, an antimalarial drug, comes into play, potentially offering a protective effect.

The current standard of care for AAV involves managing the disease itself and preventing infections, especially those caused by opportunistic pathogens. Historically, trimethoprim/sulfamethoxazole has been used to prevent Pneumocystis jirovecii pneumonia. However, this article explores the use of hydroxychloroquine as another method for infection prevention, along with its potential benefits beyond its protective effects.

This article aims to provide a comprehensive overview of the latest research on hydroxychloroquine in AAV treatment, highlighting its potential benefits, associated risks, and the future implications of this approach for patient care. We will be taking a deep dive into the current medical landscape to better understand the need for the medication.

AI Search Multiple angles on this topic

Established Uses and Safety Considerations

Hydroxychloroquine, sold under the brand name Plaquenil and others, is used to prevent and treat malaria where malaria remains sensitive to chloroquine. It is also used for rheumatoid arthritis and lupus, including systemic and discoid lupus erythematosus. The Mayo Clinic warns that some people may experience agitation, irritability, abnormal behavior, depression, or suicidal thoughts during the first month of treatment, while WebMD provides updated patient information on uses, side effects, interactions, and warnings.

Accepted Clinical Uses

Hydroxychloroquine is an established medication for treating autoimmune conditions such as rheumatoid arthritis and lupus. Cleveland Clinic also identifies it as a medication that can prevent and treat malaria. These accepted uses provide the clinical context for discussing any proposed infection-prevention role, but the source does not establish hydroxychloroquine as a standard preventive treatment for infections beyond malaria.

A Longer Clinical Context

Hydroxychloroquine's place in medicine reflects a history of use across infectious and autoimmune conditions. Its relevance to infection prevention should therefore be considered alongside its established therapeutic roles rather than assumed from preliminary hypotheses. The available material here does not provide specific dates, milestones, or foundational discoveries.

Understanding AAV and the Risk of Infections

Digital illustration of a healthy blood vessel

AAV treatments, such as rituximab, effectively suppress the immune system to control the disease. However, this immunosuppression increases the risk of infections, especially respiratory tract infections. This is a significant concern, as infections can lead to serious complications and even be life-threatening for AAV patients. The medical community faces the challenge of balancing effective disease management with minimizing infection risks.

Current recommendations often include preventative measures like trimethoprim/sulfamethoxazole to combat certain infections. However, this article explores the potential of hydroxychloroquine as an alternative or complementary approach, particularly in light of emerging research. This includes its potential protective effects against infections and the possibility of additional benefits for patients.

  • Increased Infection Risk: AAV treatments can weaken the immune system, increasing the likelihood of infections.
  • Need for Prophylaxis: Prophylactic medications are often used to prevent infections like Pneumocystis pneumonia.
  • Emerging Alternatives: Hydroxychloroquine is being investigated as a potential alternative or addition to existing preventative strategies.
AI Search Multiple angles on this topic

Evidence Still Requires Evaluation

The available material does not provide a specific recent study or review evaluating hydroxychloroquine for AAV-related infection prevention. Any proposed benefit should therefore be described as investigational rather than established. Conclusions would require direct evidence from appropriately designed research.

Limits of the Available Evidence

The supplied sources do not report results from trials of hydroxychloroquine for preventing infections associated with AAV. They therefore cannot establish whether the proposed approach succeeds or fails in that setting. Claims about effectiveness, failure, or comparative risk should remain appropriately cautious until condition-specific evidence is available.

No Direct Comparison Provided

The supplied material describes hydroxychloroquine's established uses but does not compare it with alternative infection-prevention strategies for AAV. A meaningful comparison would require evidence on effectiveness, safety, dosing, and patient outcomes across approaches. Those comparative data are not provided here.

Recent studies have highlighted the potential of hydroxychloroquine to reduce infection risks. For example, research has shown that hydroxychloroquine users had a reduced risk of infection compared to non-users. In addition, the protective effect was observed in different patient cohorts. This, along with other findings, suggests a significant role for hydroxychloroquine in protecting against infections. These findings have led to increased interest in using it as a method for treatment. This is in line with doctors trying to balance the treatment of the disease with minimizing infection risks.

Looking Ahead: Hydroxychloroquine in AAV Treatment

Hydroxychloroquine shows promise in the prevention of infections in AAV patients. This approach may offer new possibilities for improving patient outcomes. Future research, including clinical trials, will be crucial to fully understand its role and to refine treatment strategies, ensuring patients with AAV receive the best possible care. The goal is to provide the most effective and safe treatment options.

AI Search Multiple angles on this topic

A Cautious Interpretation

Hydroxychloroquine has recognized roles in malaria and autoimmune disease treatment. However, the supplied material does not establish a preventive role for hydroxychloroquine in AAV-associated infections. Any expert interpretation should distinguish established indications from unconfirmed potential applications.

Questions for Future Research

Future research could clarify whether hydroxychloroquine has any role in preventing infections among people with AAV. Such work would need to examine benefits and harms directly in the relevant patient population. Until that evidence exists, the infection-prevention potential remains uncertain.

Balancing Potential and Safety

Discussion of hydroxychloroquine's broader role must account for both its established uses and its reported safety concerns. The Mayo Clinic notes possible behavioral and mood-related effects early in treatment. This underscores the importance of careful clinical evaluation when considering any unestablished preventive application.

Patient-Centered Decisions

Patients may encounter hydroxychloroquine under brand names such as Plaquenil, particularly in the context of malaria, rheumatoid arthritis, or lupus. Clear communication is important because the medication has recognized uses but also potential adverse effects. Decisions about any proposed infection-prevention use should be individualized and discussed with a healthcare professional.

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1136/annrheumdis-2018-214508, Alternate LINK

Title: Prevention Of Infections In Patients With Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Potential Role Of Hydroxychloroquine

Subject: General Biochemistry, Genetics and Molecular Biology

Journal: Annals of the Rheumatic Diseases

Publisher: BMJ

Authors: Pavel I Novikov, Nikolai M Bulanov, Anastasiia S Zykova, Sergey V Moiseev

Published: 2018-11-24

Everything You Need To Know

1

What is antineutrophil cytoplasm antibody-associated vasculitis (AAV), and why are those affected at a higher risk of infection?

Antineutrophil cytoplasm antibody-associated vasculitis, or AAV, refers to a group of autoimmune diseases characterized by inflammation of small blood vessels. Treatments for AAV, particularly rituximab, suppress the immune system to manage the disease. However, this immunosuppression unfortunately elevates the risk of infections, making patients more vulnerable, especially to respiratory tract infections. The need to balance effective AAV management with minimizing infection risks is a critical challenge.

2

How has AAV traditionally been managed to prevent infections, and what new approach is being explored?

Traditionally, the prevention of infections in AAV patients has included prophylactic medications like trimethoprim/sulfamethoxazole to prevent Pneumocystis jirovecii pneumonia. However, a new approach is being explored that involves the use of hydroxychloroquine. This medication is being investigated for its potential to protect against infections in AAV patients, either as an alternative to, or in conjunction with, existing preventative strategies.

3

What evidence supports the use of hydroxychloroquine in preventing infections for patients with AAV?

Recent studies suggest that hydroxychloroquine may reduce the risk of infections in AAV patients. Research indicates that hydroxychloroquine users experienced a lower risk of infection compared to non-users. These findings suggest a significant role for hydroxychloroquine in protecting AAV patients against infections, leading to increased interest in its use as a method for treatment and balancing disease management with minimizing infection risks. It remains crucial to conduct clinical trials to fully understand the role of Hydroxychloroquine and refine the treatment strategies.

4

What are the potential benefits and risks associated with using hydroxychloroquine as a preventative measure for infections in AAV patients, beyond its protective effects?

The benefits of hydroxychloroquine for infection prevention in AAV patients extend to the potential for improved patient outcomes. The main appeal is that it may offer protection in addition to AAV treatment. It's critical to balance these potential benefits with a clear understanding of the drug's associated risks, including those that need to be addressed and mitigated to ensure the best possible care. While the medication may have some potential beyond the treatment of AAV and prevention of infection, further studies need to be done.

5

What future research is planned to fully understand the role of hydroxychloroquine in AAV treatment and refine treatment strategies?

Future research, including clinical trials, is crucial to fully understand the role of hydroxychloroquine in AAV treatment and to refine treatment strategies. These trials aim to provide a more comprehensive understanding of its benefits, identify the patients who are most likely to benefit from this approach, and determine the optimal dosage and duration of treatment. Additionally, research will focus on identifying and managing any potential side effects or risks associated with hydroxychloroquine use in AAV patients, ultimately ensuring they receive the safest and most effective care.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.